Language impairment in Alzheimer’s disease and benefits of acetylcholinesterase inhibitors

Steven H Ferris1
Martin Farlow2

1Alzheimer’s Disease Center, Comprehensive Center on Brain Aging, New York University Langone Medical Center, New York, NY, 2Department of Neurology, Indiana University School of Medicine, Indianapolis, IN, USA

Abstract: Alzheimer’s disease is characterized by progressively worsening deficits in several cognitive domains, including language. Language impairment in Alzheimer’s disease primarily occurs because of decline in semantic and pragmatic levels of language processing. Given the centrality of language to cognitive function, a number of language-specific scales have been developed to assess language deficits throughout progression of the disease and to evaluate the effects of pharmacotherapy on language function. Trials of acetylcholinesterase inhibitors, used for the treatment of clinical symptoms of Alzheimer’s disease, have generally focused on overall cognitive effects. However, in the current report, we review data indicating specific beneficial effects of acetylcholinesterase inhibitors on language abilities in patients with Alzheimer’s disease, with a particular focus on outcomes among patients in the moderate and severe disease stages, during which communication is at risk and preservation is particularly important.

Keywords: Alzheimer’s disease, donepezil, cognition, language, communication, clinical trials

Introduction

Alzheimer’s disease (AD) is the most common etiology for dementia. Worldwide, it is currently estimated that 35 million people have AD or a related dementia, and with increasing life expectancy, global prevalence is projected to increase to around 66 million by 2030 and to more than 115 million by 2050. In the United States, 5.4 million individuals of all ages are currently estimated to have AD, with the vast majority (>95%) aged older than 65 years. With increasing life expectancy and aging of the baby boomer generation, the elderly US population (age ≥ 65 years) is projected to nearly double to 71 million by 2030. Applying this population increase to current prevalence estimates, barring medical breakthroughs to prevent, slow, or stop the disease, 16 million elderly Americans are projected to have AD by 2050. As with many other diseases of the elderly, AD is associated with significant burden on the person with the disease, on their caregivers, and on society as a whole through the considerable cost of disease-related care. At present, annual AD-related care costs in the United States are around $200 billion.

Patients with AD progress through mild, moderate, and severe stages, and more than half are expected to be at the moderate or severe stages of the disease at any given time (Figure 1). Progressive cognitive decline is the fundamental feature of AD symptomatology, and is characterized by episodic memory loss and impairments in attention/concentration, orientation, judgment, visuospatial abilities, executive function, and language. Although the relative importance of the decline in these different...
cognitive domains remains undefined, worsening language abilities, or aphasia, has been suggested to have more clinical relevance than other domains, such as memory, orientation, and reasoning, in progression from the moderate to severe stages of AD, given that decline in language has been shown to correlate with noncognitive items, such as personal care, hobbies, occupations, and behavior.7 Language impairment is a significant issue in most patients as they pass through moderate into severe disease stages. Yet even early on in the disease state, aphasia is an important characteristic; recently published criteria for the clinical diagnosis of AD include language impairment at onset in one of the subtypes.8 Differentiation between AD and other types of dementia, such as primary progressive aphasia, one of the major types of frontotemporal dementia, may be made on the basis of association with causative mutations or different pathologies. However, pathological studies9,10 have shown that 22%–28% of cases of primary progressive aphasia are caused by AD.

Herein we discuss the progressive language impairment in patients with AD and the associated psychosocial burden, and review the published literature on clinical studies of the benefits of acetylcholinesterase inhibitors (AChEIs) in managing language deficits in patients with AD.

Language impairment in AD

Language impairment in AD is primarily a result of decline in semantic and pragmatic levels of language processing.11 Semantic processing involves language content, such as words and their meaning, and the associated impairments include difficulties with word finding, naming, and word comprehension, as well as semantic paraphasia (choosing incorrect words), empty speech (using ambiguous referents), inventing words, and loss of verbal fluency.11 Pragmatic processing goes beyond words and their meaning and concerns language adaptation to the social situation.11 Examples of pragmatic problems are speaking too much at inappropriate times, talking too loudly, repeating ideas, and digressing from the topic. Deficits in pragmatic processing may also be influenced by other AD symptoms, such as impairments in memory and concentration, and disinhibition. However, it is thought that semantics and pragmatics are interdependent such that semantic deficits in word finding and naming may contribute to pragmatic problems in maintaining the topic of conversation or may overwhelm the cognitive ability of the patient, resulting in shouting or use of profanity.11,12

Although subtle language deficits are detected in the early stages of AD, the mechanics of speech (ie, phonological and syntactic performance) appear to be well preserved, and at least some of the perceived deficits result from dysfunction in nonlinguistic domains such as attention and executive control.13 In the early stages of AD, language impairment involves lexical retrieval problems, loss of verbal fluency, and breakdown in comprehension of higher order written and spoken languages. In the moderate and severe stages of AD,
the loss of verbal fluency is profound, with breakdown of comprehension and literal and semantic paraphrases prominent (Table 1); in very severe AD, speech is often restricted to echolalia and verbal stereotypy.4,14

**Psychosocial burden of language impairment on patients and caregivers**

During the moderate to severe stages of AD, the patients’ language declines and deficits often result in a loss of ability to express their needs, which in turn affects their quality of life, prognosis, and social relationships, and can contribute significantly to patient and caregiver burden.4,13 Indeed, with progressive loss of language and other cognitive abilities, these patients lose their autonomy, and quality of life worsens as they become unable to sustain normal daily activities; as has been demonstrated in a study showing that several cognitive abilities, including expressive language, are required to maintain function in activities of daily living.16 Emotional distress/depression, severity of language deficit, and communication disability are some predictors of health-related quality of life in patients with language impairments.17 To this effect, assessment of health-related quality of life in a hospital-based, long-term care patient population showed that language impairments had a stronger association with negative quality of life than did cancer, after controlling for age, gender, and other diagnoses.18 In addition to predicting quality of life, severity of language impairment was suggested to be a predictor of mortality,19 with verbal frequency being the most significant neuropsychological predictor.20

### Table 1 Language impairments in Alzheimer’s dementia

<table>
<thead>
<tr>
<th>Early stage</th>
<th>Moderate-severe</th>
</tr>
</thead>
<tbody>
<tr>
<td>Spontaneous speech</td>
<td>Fluent, grammatical</td>
</tr>
<tr>
<td>Paraphasic errors</td>
<td>Semantic</td>
</tr>
<tr>
<td>Repetition</td>
<td>Intact</td>
</tr>
<tr>
<td>Naming</td>
<td>Impaired (mild)</td>
</tr>
<tr>
<td>Comprehension of words</td>
<td>Intact</td>
</tr>
<tr>
<td>Syntactic comprehension</td>
<td>Intact</td>
</tr>
<tr>
<td>Reading</td>
<td>± intact</td>
</tr>
<tr>
<td>Writing</td>
<td>± intact</td>
</tr>
<tr>
<td>Word and object knowledge (semantic knowledge)</td>
<td>Intact for more frequently used words and objects; impaired for less frequently used words and objects</td>
</tr>
</tbody>
</table>


An earlier study in elderly patients showed that language impairments were associated with both behavioral and psychological symptoms of dementia. Specifically, impairment of expressive language was associated with delusions and with a tendency for depression.21 In addition, studies of the social relationships of stroke patients found that those experiencing language impairments were most likely to find it difficult to maintain existing friendships and often found themselves withdrawing from social contact.22 Progressive loss of communication via language has also been shown to trigger other behavioral problems, such as agitation, restlessness, and wandering in patients with dementia.11

When loss of memory, loss of judgment, and impaired communication increase the need for supervision and caregiving, a frequent consequence is an increase in caregiver burden.2 Approximately 80% of care is provided by family caregivers,2 so it is no surprise that family members who self-report caring for relatives with dementia indicated that communication breakdown often led to decline in the quality of their interaction and relationship.11

**Measuring language impairment in AD**

Rating scales are essential tools for diagnosis, staging, and monitoring of AD symptoms in response to therapy. Given that cognition is the primary impairment, most AD assessments have been more focused on rating overall cognitive deficits than on functional or behavioral symptoms.23 Because of the centrality of language to cognitive function, language-specific scales designed to measure progressive language deficits through the course of AD progression have been developed in recent years.14

In designing tools to assess language impairment, fluency in spontaneous speech, naming or word-finding, grammar, and paraphasic errors are key aspects of the assessment and are required for diagnosis of the types of dementia.14 Formal language assessment involves the following domains: naming (eg, the Boston Naming Test), repetition of words/sentences, comprehension (auditory and semantic knowledge), reading, and writing.14 There are a number of disease severity-appropriate scales that are currently used in the clinical trial setting to measure changes in cognitive deficits, including language. For mild and moderate AD, the Mini-Mental State Examination (MMSE) and the cognitive subscale of the Alzheimer’s Disease Assessment Scale (ADAS-cog) were designed to assess three core symptom domains, ie, memory, language, and praxis.24 With high inter-rater and test-retest reliability, the ADAS-cog, consisting of 11 items and three
domains, is now considered the “gold standard” measure of cognitive performance in mild to moderate AD in clinical trials. However, for moderate to severe AD, the MMSE and ADAS-cog scales are considered relatively insensitive for measuring disease progression as a result of floor effects. It is also noteworthy that neither the MMSE nor the ADAS-cog are specific language assessments and more specific language measures (eg, the Boston Naming Test) may be useful in cases where further evaluation of language is warranted.

In moderate to severe and severe AD, the Severe Impairment Battery (SIB) is used to evaluate the severity of cognitive dysfunction across nine cognitive domains, ie, language, memory, praxis, visuospatial ability, social interaction, attention, orientation, construction, and orienting to name. The sensitivity, reliability, and validity of the SIB are well established, and administration requires about 30 minutes. Because of the importance of language to cognitive function, 24 of the 51 total items and subitems in the full SIB scale assess language ability and comprise the SIB language subscale. It is notable that, although the full SIB assesses nine core cognitive domains and the ADAS-cog only three core domains, a larger proportion of the full SIB (47%, 24 of 51 total items) pertains to evaluation of language function, in contrast with only 28% of the ADAS-cog scale. It is possible that the larger proportion of language items in the SIB, combined with the significant language impairment seen among patients at the moderate and severe disease stages, contributes to the additional sensitivity of the SIB in measuring change in cognition in more advanced AD.

In a recent factor analysis, the 24 items in the SIB language subscale were analyzed to identify those most relevant to language function. Using baseline data from four placebo-controlled trials of memantine in moderate to severe AD, 21 of the 24 items were included in the SIB language scale (SIB-L). Pearson correlation of SIB-L with the full SIB was high ($r = 0.943$), indicating that the SIB-L scale maintains the sensitivity of the complete SIB scale. More recently, a new 21-item SIB-derived language subscale [SIB(lang)] was also constructed by performing a similar factor analysis on the 24 language items using baseline data from a single large randomized trial of donepezil 23 mg/day versus donepezil 10 mg/day in moderate to severe AD. To assess further the clinical utility of the SIB-derived language scales, SIB-L and SIB(lang) scores were correlated with other severity measures (MMSE, severe version of the Alzheimer’s disease Cooperative Study-Activities of Daily Living Inventory [ADCS-ADL-sev] and the Clinician’s Interview-Based Impression of Severity-plus caregiver input/Clinician’s Interview-Based Impression of Change-plus caregiver input [CIBIS-plus/ CIBIC-plus]). At baseline and at end point, correlations between the SIB-derived language scales and the MMSE were strong, but were weak to moderate with ADCS-ADL-sev and CIBIS-plus; however, correlations between changes in scores on the SIB-derived language scales and changes in scores on the MMSE were relatively weak. Furthermore, correlations between changes in scores on the SIB-derived language scales and baseline ADCS-ADL-sev and CIBIC-plus scores were also weak. These observations suggest that (1) cognition, as measured by the MMSE, is strongly related to language abilities that are measured by SIB-derived language scales, but changes in cognition and changes in language track differently over time, and (2) there is little relationship between baseline functional status and treatment-derived changes in language abilities.

**Benefits of AChEI pharmacotherapy on language function**

Currently there are three AChEIs approved by the US Food and Drug Administration (FDA) for the treatment of AD in use in clinical practice. Donepezil, rivastigmine, and galantamine are indicated for the treatment of mild to moderate AD. Donepezil is also approved for the treatment of moderate to severe and severe AD. Although these agents have been approved for more than 10 years, to date, no clinical trial has been performed to evaluate the effects of AChEIs on language specifically, and the focus has been primarily on the overall effects of AChEIs on cognition. However, based on several cognitive domain analyses and the recent development of SIB-derived language scales, it is now possible to review the data for the benefits of AChEIs on language function in patients with AD.

**Donepezil**

A number of studies in patients with moderate or severe AD have examined the treatment effect of the 10 mg/day dose of donepezil on individual cognitive domains, including language. Based on an SIB domain analysis using data from a placebo-controlled study in severe AD, patients treated with donepezil 10 mg/day for 6 months showed improvements in eight of nine SIB domains, with a significant difference between donepezil and placebo shown for language (as well as the praxis and visuospatial domains). In a similar global study of patients with severe AD receiving donepezil 10 mg/day for 6 months, language was again improved from baseline, but declined in the placebo group. Similar language benefits with donepezil 10 mg/day were reported in
two analyses using pooled data from studies of patients with moderate to severe or severe AD; in both analyses, language improved from baseline with donepezil and declined with placebo. 

Consistent with these findings, a recent post hoc analysis reported that, after 6 months’ treatment with donepezil 10 mg/day, patients with moderate to severe AD showed less worsening in language compared with those receiving placebo. 

Recently, a higher dose of donepezil (23 mg/day) was approved by the FDA for the treatment of moderate to severe AD based on outcomes from a large multinational, double-blind trial comparing donepezil 23 mg/day with donepezil 10 mg/day. 

To determine whether treatment with this higher dose was associated with specific language benefits in patients with moderate and severe AD, a post hoc analysis was performed using the SIB-L and SIB(lang) scales. 

Data from this analysis showed that, after 24 weeks of treatment, donepezil 23 mg/day was associated with improved language function, whereas donepezil 10 mg/day was associated with a decline in language function (Figure 2). Moreover, the significant language benefits of donepezil 23 mg/day over 10 mg/day were not only evident in the overall study population, but also more prominent in patient subgroups based on more advanced baseline AD (MMSE scores 0–16) and on concomitant use of memantine. 

In this study, donepezil 23 mg showed a 0.8-point improvement over the lower dose measured using the SIB-L (total score range 0–41). The “real-world” clinical meaningfulness of this 0.8-point benefit on the SIB-L was not assessed. However, it is noteworthy that this is an improvement over an active therapy, not placebo, and based on studies with other AChEIs in moderate and/or severe populations, untreated patients with advanced AD would likely show a decline in SIB-L scores over a similar study period.

The greater effect of donepezil 23 mg/day over donepezil 10 mg/day on language function may be due to higher-dose donepezil facilitating greater acetylcholinesterase inhibition and thereby increasing cholinergic function in regions of the brain controlling speech and language. Another hypothesis is that the observed language benefits could be driven by enhanced effects of the 23 mg/day dose on regions of the brain controlling other cognitive processes, such as attention and memory. It seems logical that attention deficits could substantially influence a patient’s language ability as measured by the SIB-L and SIB(lang) scales, and there is clearly some overlap between certain aspects of language impairment, such as difficulties with word finding, and general memory problems. Further prospective studies are needed to determine the direct and indirect mechanisms whereby donepezil 23 mg/day provides improved language benefits over the donepezil 10 mg/day dose.

**Rivastigmine**

Although oral formulations of rivastigmine have been approved for the treatment of mild to moderate AD since 2000 and transdermal formulations since 2007, data pertaining to the treatment effect on individual cognitive domains are limited. In one retrospective pooled analysis designed to assess the treatment effect of rivastigmine versus placebo on the individual domains of the ADAS-cog in patients with mild to moderate AD, language declined with both rivastigmine doses and with placebo, although the extent of the decline was significantly less with the higher dose rivastigmine capsule versus placebo (Figure 3). Conversely, in a similar clinical study, treatment with the rivastigmine transdermal patch tended to show
language improvements from baseline and a significant benefit over placebo in patients with mild to moderate AD. However, in this study, treatment with the higher-dose rivastigmine capsule did not show significant language benefits over placebo.36

**Galantamine**

Like rivastigmine, galantamine has been approved for the treatment of mild to moderate AD for about a decade. However, data on the effects of this treatment on individual cognitive domains, including language, are lacking. In a single large multinational study designed to assess the effects of treatment with galantamine in patients with severe AD, galantamine was associated with improvement on six of the nine SIB domains, with significant benefits over placebo reported for the memory, praxis, and visuospatial domains (Figure 4).38 In this study, language improved from baseline
with galantamine, but declined with placebo; however, the difference between the effects of galantamine and placebo on language function was not statistically significant.

**Conclusion**

Language impairment is one of the primary components of cognitive decline in AD and contributes significantly to reduced quality of life for patients and to caregiver burden. Although clinical trials of AChEIs in patients with AD have traditionally focused on benefits on the core symptoms of cognition, functional activity, and behavior, there are clinical data available, predominantly from post hoc subanalyses, demonstrating that AChEIs can provide language benefits in patients with AD. Prospective studies, ideally using specific language measures, will be necessary to define clearly the benefits of AChEIs on language in patients with AD. However, the existing exploratory data indicate that language benefits associated with AChEIs may be apparent even in the more advanced stages of disease, when preservation or improvement of language function is particularly important, both for the patients and their caregiving network.

**Acknowledgments**

Editorial support in the development of this manuscript was provided by R Daniel and K Ayling-Rouse of Parexel, and was funded by Eisai Inc and Pfizer Inc.

**Disclosure**

SHF has served as a paid scientific consultant to Accera, Baxter, Bristol-Myers Squibb, Eisai, Elan, Eli Lilly, Janssen AI, MedAvante, Merck, Merz, Neuronix, Novartis, Otsuka, Pfizer, Toyama, and United BioSource. His institution has received grant/contract support for clinical trials from Baxter, Bristol-Myers Squibb, Eisai, Eli Lilly, Janssen AI, Merck, Neuronix, Pfizer, Roche, and Takeda. He also has stock options from Accera, Intellect Neurosciences, MedAvante and Raptor, and owns stock in Lexicon.

MF has served as a paid consultant for Accera, Alltech, Astellas, Bayer, Bristol-Myers Squibb, Eisai Medical Research, GE Healthcare, Helicon, MedAvante, Mediation, Inc., Merck and Co, Inc., Novartis Pharma, Pfizer, Prana Biotech, QR Pharma, Sanofi-aventis Groupe, Schering-Plough, Lilly, Shire Pharmaceuticals, and Toyama, is a paid speaker for Eisai, Forest, Novartis, and Pfizer, and receives research support from Eisai, Eli Lilly and Co, Genentech, Novartis Pharm, and Roche.

**References**